• +91 9169164321 (Asia)
  • +1(646)-781-7170 (Int'l)
  • help@24lifesciences.com
Cart (0)

Bone Metastasis - Pipeline Review, H1 2020

report cover
  • 30 April 2020
  • Pharmaceuticals
  • 127 Pages
  • Report Code: 24LS-1841
  • Formate :   
Download FREE Report Sample Download PDF File

Bone Metastasis Pipeline Review H1 -MARKET ADVISORY SERVICES

Bone Metastasis - Pipeline Review, H1 2020

Summary

We latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Pipeline Review, H1 2020, provides an overview of the Bone Metastasis (Oncology) pipeline landscape.

Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. The predisposing factors include certain kinds of cancer (breast, prostate, lung, thyroid, and kidney cancers). Treatment options for bone metastasis are chemotherapy, surgery and radiation therapy.

Report Highlights

We Pharmaceutical and Healthcare latest pipeline guide Bone Metastasis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Bone Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 3, 8, 3, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 7, 1 and 1 molecules, respectively.

Bone Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Metastasis (Oncology).
- The pipeline guide reviews pipeline therapeutics for Bone Metastasis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bone Metastasis (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bone Metastasis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bone Metastasis (Oncology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bone Metastasis (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bone Metastasis (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Introduction
Bone Metastasis - Overview
Bone Metastasis - Therapeutics Development
Bone Metastasis - Therapeutics Assessment
Bone Metastasis - Companies Involved in Therapeutics Development
Bone Metastasis - Drug Profiles
Bone Metastasis - Dormant Projects
Bone Metastasis - Discontinued Products
Bone Metastasis - Product Development Milestones
Appendix
List of Tables

Number of Products under Development for Bone Metastasis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Bone Metastasis - Pipeline by Ablynx NV, H1 2020

Bone Metastasis - Pipeline by Altum Pharmaceuticals Inc, H1 2020

Bone Metastasis - Pipeline by Amgen Inc, H1 2020

Bone Metastasis - Pipeline by Bayer AG, H1 2020

Bone Metastasis - Pipeline by BiologicsMD Inc, H1 2020

Bone Metastasis - Pipeline by BioNTech SE, H1 2020

Bone Metastasis - Pipeline by CSPC Pharmaceutical Group Ltd, H1 2020

Bone Metastasis - Pipeline by Deciphera Pharmaceuticals Inc, H1 2020

Bone Metastasis - Pipeline by Eli Lilly and Co, H1 2020

Bone Metastasis - Pipeline by Genor BioPharma Co Ltd, H1 2020

Bone Metastasis - Pipeline by Hengenix Biotech Inc, H1 2020

Bone Metastasis - Pipeline by ITM Isotopen Technologien Munchen AG, H1 2020

Bone Metastasis - Pipeline by Jiangsu Rhentai Pharmaceutical Biotechnology Co Ltd, H1 2020

Bone Metastasis - Pipeline by Jiangsu T-mab BioPharma Co Ltd, H1 2020

Bone Metastasis - Pipeline by Livzon MabPharm Inc, H1 2020

Bone Metastasis - Pipeline by Lupin Ltd, H1 2020

Bone Metastasis - Pipeline by Luye Pharma Group Ltd, H1 2020

Bone Metastasis - Pipeline by MetCure Therapeutics LLC, H1 2020

Bone Metastasis - Pipeline by Mirati Therapeutics Inc, H1 2020

Bone Metastasis - Pipeline by NeuClone Pty Ltd, H1 2020

Bone Metastasis - Pipeline by Oncolix Inc, H1 2020

Bone Metastasis - Pipeline by Orion Biotechnology Canada Ltd, H1 2020

Bone Metastasis - Pipeline by Qilu Pharmaceutical Co Ltd, H1 2020

Bone Metastasis - Pipeline by R Pharm, H1 2020

Bone Metastasis - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2020

Bone Metastasis - Pipeline by Serene LLC, H1 2020

Bone Metastasis - Pipeline by Sonnet BioTherapeutics Inc, H1 2020

Bone Metastasis - Pipeline by Terpenoid Therapeutics Inc, H1 2020

Bone Metastasis - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2020

Bone Metastasis - Dormant Projects, H1 2020

Bone Metastasis - Dormant Projects, H1 2020 (Contd..1), H1 2020

Bone Metastasis - Dormant Projects, H1 2020 (Contd..2), H1 2020

Bone Metastasis - Discontinued Products, H1 2020List of Figures

Number of Products under Development for Bone Metastasis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020
Ablynx NV

Altum Pharmaceuticals Inc

Amgen Inc

Bayer AG

BiologicsMD Inc

BioNTech SE

CSPC Pharmaceutical Group Ltd

Deciphera Pharmaceuticals Inc

Eli Lilly and Co

Genor BioPharma Co Ltd

Hengenix Biotech Inc

ITM Isotopen Technologien Munchen AG

Jiangsu Rhentai Pharmaceutical Biotechnology Co Ltd

Jiangsu T-mab BioPharma Co Ltd

Livzon MabPharm Inc

Lupin Ltd

Luye Pharma Group Ltd

MetCure Therapeutics LLC

Mirati Therapeutics Inc

NeuClone Pty Ltd

Oncolix Inc

Orion Biotechnology Canada Ltd

Qilu Pharmaceutical Co Ltd

R Pharm

Reliance Life Sciences Pvt Ltd

Serene LLC

Sonnet BioTherapeutics Inc

Terpenoid Therapeutics Inc

Zhejiang Hisun Pharmaceutical Co Ltd

CHOOSE YOUR BUYING OPTION COVID-19 Revised Pricing Of the Month

SECURITY ASSUREDpayment image

Frequently Asked Questions ?

  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Upto Working 24 to 48 hrs

  • Upto 72 hrs max - Weekends and Public Holidays

  • Online Payments with PayPal and CCavenue

  • Wire Transfer/Bank Transfer

  • Email

  • Hard Copy

CHECK TODAYS BEST PRICE

BEST PRICE: $1680

SOME OF OUR CLIENTS

OUR KEY POINTS

  • Comprehensive Research

    Offers Penetrative insights & holistic understanding of the market

  • Data Accuracy & Reliability

    Strictly follows the Research Meth-odology for flawless results

  • Competitive Pricing

    Ensure the best and affordable pricing

  • Security & Confidentiality

    All your transactions are secured end-to-end, ensuring a satisfactory purchase